FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology, namely to an effector composition of constructed CRISPR-Cas type I for splitting DNA containing a type I CRISPR-Cas subunit protein, a type I guide polynucleotide and a type I CRISPR engineered protein mCas3 (mCas3).
EFFECT: invention is effective for splitting double-stranded DNA (dsDNA).
12 cl, 49 dwg, 53 tbl, 26 ex
| Title | Year | Author | Number |
|---|---|---|---|
| KIR3DL3 INHIBITORY RECEPTOR OF IMMUNE SYSTEM AND USE THEREOF | 2020 |
|
RU2827900C1 |
| COMPOSITIONS AND METHODS OF PRODUCING (R)-RETICULIN AND ITS PRECURSORS | 2014 |
|
RU2729065C2 |
| ANTIBODIES TO ENTPD2, TYPES OF COMBINATION THERAPY AND METHODS FOR USING ANTIBODIES AND TYPES OF COMBINATION THERAPY | 2019 |
|
RU2790991C2 |
| GREMLIN-1 INHIBITOR FOR THE TREATMENT OF BONE FRACTURE OR BONE DEFECT | 2019 |
|
RU2790992C2 |
| CONJUGATES OF ANTIBODY TO CCR7 AND DRUG | 2018 |
|
RU2777662C2 |
| IMMUNOGLOBULIN CONSTANT REGION FC-RECEPTOR BINDING AGENTS | 2008 |
|
RU2729829C2 |
| METHODS AND COMPOSITIONS FOR PPO-HERBICIDAL TOLERANCE | 2018 |
|
RU2797237C2 |
| ANTIBODIES BINDING TO HUMAN CANNABINOID RECEPTOR 1 (CB1) | 2015 |
|
RU2730674C2 |
| TREATMENT AND INHIBITION OF INFLAMMATORY LUNG DISEASES IN PATIENTS WITH RISK ALLELES IN GENES ENCODING IL33 AND IL1RL1 | 2018 |
|
RU2776241C2 |
| ANTI-LILRB1 ANTIBODY AND USES THEREOF | 2021 |
|
RU2813373C1 |
